Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;44(5):367-370.
doi: 10.1007/s40261-024-01360-4. Epub 2024 Apr 29.

PB006: A Natalizumab Biosimilar

Matt Shirley  1
Affiliations
Review

PB006: A Natalizumab Biosimilar

Matt Shirley. Clin Drug Investig. 2024 May.

Erratum in

Abstract

PB006 (Tyruko®) is the first biosimilar of the reference monoclonal anti-α4-integrin antibody natalizumab. It is approved for use in the same indications for which reference natalizumab is approved, as a single disease-modifying therapy in adults with highly active relapsing-remitting multiple sclerosis (RRMS). PB006 has similar physicochemical and pharmacodynamic properties to those of reference natalizumab, and the pharmacokinetic similarity of the agents has been demonstrated in a study in healthy subjects. PB006 demonstrated clinical efficacy similar to that of reference natalizumab in patients with RRMS, and was generally well tolerated in this population. The tolerability, safety and immunogenicity profiles of PB006 were similar to those of reference natalizumab, and switching from reference natalizumab to PB006 appeared to have no impact on tolerability or immunogenicity. The role of reference natalizumab in the management of RRMS is well established and PB006 provides an effective biosimilar alternative for patients requiring natalizumab therapy.

PubMed Disclaimer

Conflict of interest statement

During the peer review process, the manufacturer of PB006 was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Matt Shirley is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Figures

Fig. 1
Fig. 1
Design of the phase III ANTELOPE trial in patients with relapsing-remitting multiple sclerosis [4]. EOS end-of-study, wk(s) week(s)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. European Medicines Agency. Tyruko: EU summary of product characteristics. 2023. https://www.ema.europa.eu. Accessed 02 Apr 2024.
    1. European Medicines Agency. Tyruko: European public assessment report. 2023. https://www.ema.europa.eu. Accessed 02 Apr 2024.
    1. Wessels H, von Richter O, Velinova M, et al. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. Expert Opin Biol Ther. 2023;23(12):1287–97. 10.1080/14712598.2023.2290530 - DOI - PubMed
    1. Hemmer B, Wiendl H, Roth K, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial. JAMA Neurol. 2023;80(3):298–307. 10.1001/jamaneurol.2022.5007 - DOI - PMC - PubMed
    1. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802–12. 10.1002/ana.24286 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources